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ABSTRACT
It is expected that a large amount of data related to diabetes and other chronic diseases
will be generated. However, databases constructed without standardized data item sets
can be limited in their usefulness. To address this, the Collaborative Committee of Clinical
Informatization in Diabetes Mellitus was established in 2011 by the Japan Diabetes Society
and Japan Association for Medical Informatics. The committee has developed core item
sets and self-management item sets for diabetes mellitus, hypertension, dyslipidemia, and
chronic kidney disease in collaboration with the Japanese Society of Hypertension, Japan
Atherosclerosis Society, Japanese Society of Nephrology, and Japanese Society of Labora-
tory Medicine, as well as a mapping table that aligns the self-management item sets with
the Japanese standardized codes for laboratory testing. The committee also determined
detailed specifications for implementing the four self-management item sets in personal
health record (PHR) applications to facilitate risk stratification, the generation of alerts using
information and communications technology systems, the avoidance of data input errors,
and the generation of reminders to input the self-management item set data. The
approach developed by the committee may be useful for combining databases for various
purposes (such as for clinical studies, patient education, and electronic medical record sys-
tems) and for facilitating collaboration between PHR administrators.
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SPECIAL REPORT
BACKGROUND AND AIMS
Many databases have been developed to store and generate
information about diabetes mellitus and other chronic dis-
eases1,2, but their subsequent use can be limited by inconsistent
data standards, such as the precise sets of data items used, and
they may therefore have limited utility beyond their initially
deﬁned roles. Recently, there has been a rapid expansion of
digitization in clinical practice and research. When appropriate
information standards are deﬁned before a new database is cre-
ated, it may then be possible to reuse the database for other
purposes. For example, a database developed for tracking infor-
mation about patient self-monitoring of diabetes might then be
used for clinical research, establishing evidence-based quality
indicators, or facilitating regional medical cooperation.
In 2010, the Japan Diabetes Society (JDS) and the Japan
Association for Medical Informatics (JAMI) established the Col-
laborative Committee for Clinical Informatization in Diabetes
Mellitus (CCCIDM) to review the digitalization of clinical data
about diabetes mellitus. The present article is a report of the
work of the committee in collaboration with six Japanese aca-
demic associations: the JDS and JAMI, as well as the Japanese
Society of Hypertension (JSH), the Japan Atherosclerosis Soci-
ety (JAS), the Japanese Society of Nephrology (JSN), and the
Japanese Society of Laboratory Medicine (JSLM, which partici-
pated from 2015). The report introduces the sets of data items
established by the committee in 2015 for diabetes mellitus and
the associated chronic diseases hypertension, dyslipidemia, and
chronic kidney disease (CKD), as well as the committee’s rec-
ommended data conﬁgurations, established in August 2018, for
personal health record (PHR) applications, which was the ﬁrst
use of the data sets.
MATERIALS AND METHODS
By the end of 2011, CCCIDM developed a core data item set
(CIS) that listed the minimum set of data items necessary for
diabetes-related databases. However, the CIS alone could not be
used in databases without additional data items. CCCIDM
therefore proposed a self-management item set (SMIS), which
may be useful for disease management by diabetic patients
themselves based on the CIS developed by a working group
sponsored by the Japanese Cabinet Secretariat and chaired by
Professor Emeritus Naoko Tajima of Jikei University School of
Medicine, who was also the ﬁrst chairperson of the CCCIDM.
Two other members of the CCCIDM also participated in the
working group. The SMIS for diabetes was approved by the
working group in 2012 and was subsequently approved by
CCCIDM.
Because patients with diabetes often have other chronic dis-
eases, it can be useful to combine data about diabetes mellitus
with data about other chronic diseases. Therefore, in addition
to diabetes mellitus, CCCIDM selected hypertension, dyslipi-
demia, and CKD for consideration because (i) they are associ-
ated with high rates of morbidity, (ii) they are associated with
considerable personal and socioeconomic burdens, (iii) they are
preventable through patient self-management, and (iv) they can
be evaluated and monitored using clear clinical parameters,
such as blood testing and lifestyle monitoring. After selecting
these diseases, CCCIDM invited the Japanese academic associa-
tions for each disease (JSH, JAS, and JSN) to form a collabora-
tive extended committee (CEC) to establish consistent
overlapping data item sets for all four diseases with the support
of the Japanese Cabinet Secretariat. The SMISs for hyperten-
sion, dyslipidemia, and CKD were established in combination
with the CISs in 2014 and were subsequently published on
JAMI’s website3. The CIS and SMIS for each disease were stan-
dardized in terms of data item name, granularity, and expres-
sion or unit used.
In 2015, the JSLM was included in the CEC. Since 2016, the
CEC has collaborated with a PHR project entitled ‘Research on
standardization and establishment of a business model for pre-
venting the aggravation of lifestyle-related diseases, in coopera-
tion with medical insurers, disease management companies, and
medical institutions,’ administered by the Medical Information
System Development Center (MEDIS-DC) and sponsored by
the Japan Agency for Medical Research and Development
(AMED). The aim of that project was to develop SMISs for
implementation in PHR applications by mapping them to ver-
sion 10 of the Japan Laboratory Analysis Codes (JLAC10)4.
These codes are the Japanese standard for laboratory testing and
can be mapped to logical observation identiﬁer names and
codes, which are international common terms (a set of identi-
ﬁers, names, and codes) for identifying health measurements,
observations, and documents5. The CEC subsequently deter-
mined the boundary values and thresholds for risk stratiﬁcation,
as well as values that could be used to provide smartphone alerts
to various users, including patients, family members, and medi-
cal staff, based on standard clinical guidelines for the chronic
diseases. The CEC also identiﬁed parameters that could be used
to avoid data input errors and to prompt users to input data
into the PHR within the appropriate time interval for each item.
RESULTS
Between 2011 and 2014, the CEC established CISs and SMISs
that included the CISs for each of the four chronic diseases
and revised them in 2018 (Figures 1 and 2). The CISs com-
prised 14 items for diabetes mellitus, 13 for hypertension, 13
for dyslipidemia, and 12 for CKD. By eliminating overlapping
items, the overall number of CIS items was reduced from 52 to
23 (Figure 2). The SMISs comprised 22 items for diabetes mel-
litus, 18 for hypertension, 15 for dyslipidemia, and 23 for CKD.
After eliminating overlapping items, the total number of SMIS
items was reduced from 78 to 41 (Figure 2).
The four CISs and four SMISs were approved by the admin-
istrative boards of all six associations in 2015 (the ﬁrst edition)
and in 2018 (the second edition). During 2016 and in August
2018, the CEC developed detailed speciﬁcations (Tables S1 to
S6) for implementing the four SMISs in PHR applications,
described as ‘recommended conﬁgurations for the PHRs of
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chronic diseases.’ This was performed in collaboration with a
PHR project by MEDIS-DC.
Because the standard clinical guidelines ask stricter indicators
for patients with chronic diseases than for healthy people, the
CEC determined a basic conﬁguration for healthy people
(Table S1) and associated conﬁgurations for diabetes mellitus
(Table S2), hypertension (Table S3), dyslipidemia (Table S4),
CKD (Table S5), and coronary heart disease (Table S6), which
were added during a discussion by the CEC for risk assessment
of the four chronic diseases. The tables show the various strict
values for reminders, alerts, or thresholds for risk stratiﬁcations.
PHR applications should use the basic conﬁguration (Table S1)
to detect possibility of pre-diseases (yellow) or the onset of dis-
eases (orange and red) when the user does not have any pre-
viously diagnosed disease. And the additional conﬁguration for
the appropriate chronic disease to know the risk of serious
complications of the diseases (green; minimum risk, yellow;
light risk, orange; moderate risk, red; high risk) when the
patient experiences the onset of the disease (Table S2 to S6). If
the PHR has various conﬁgurations because the patient suffers
from more than one of the chronic diseases, the strictest con-
ﬁguration should be used.
The CEC deﬁned fasting and non-fasting conditions for the
conﬁguration of PHRs for chronic diseases. The fasting condi-
tion follows fasting for 10 h (although the consumption of
water and non-calorie tea are acceptable). The values for alerts
and risk stratiﬁcation in the conﬁguration of the PHR refer to
fasting condition results for the tests for blood glucose (SMIS-
ID 10 in Figure 2), triglycerides (SMIS-ID 18), urine glucose
(SMIS-ID 28), and self-monitored blood glucose (no ID). The
CEC recommends that PHR applications include a function to
identify whether these four items have been measured under
the fasting condition.
The SMIS and recommended PHR conﬁguration have sev-
eral lipid-related indicators, including levels of low-density
lipoprotein (LDL) cholesterol (by direct assay), total cholesterol,
high-density lipoprotein (HDL) cholesterol, and triglycerides.
Additional indicators, such as LDL cholesterol by the Friede-
wald formula and non-HDL cholesterol, can be calculated from
data in the SMIS. However, serum triglyceride levels are
affected by eating, and some indicators are unstable in blood
samples with high triglyceride levels. Thus, the JAS Guidelines
for Prevention of Atherosclerotic Cardiovascular Diseases 20176
has speciﬁed the following according to triglyceride levels: when
1 Height cm
2 Weight kg
3 Systolic Blood Pressure mmHg
4 Diastolic Blood Pressure mmHg
5 LDL Cholesterol mg/dL
6 HDL Cholesterol mg/dL
7 Smoking Yes, No, Yes in the past
8 Serum Creatinine mg/dL
9 Urine Protein –, ±, +, 2 + v, 3 + or over
10 Blood Glucose mg/dL
11 Age diagnosed as Diabetes
Mellitus  
under 10y.o, 10's, 20's, , , 70's, 80y.o. or over, Not yet, 
Unknown
12 HbA1c    1 %
13 ALT IU/L
14 Diabetic Retinopathy Yes, No, Unknown
15 Age diagnosed as Hypertension under 10y.o, 10's, 20's, , , 70's, 80y.o. or over, Not yet, 
Unknown
16 Serum Potassium mEq/L
17 Abnormality on ECG Yes, No, Unknown
18 Triglyceride mg/dL
19 Age diagnosed as Dyslipidemia under 10y.o, 10's, 20's, , , 70's, 80y.o. or over, Not yet, 
Unknown
20 Past History of Coronary
Diseases 
Yes (by contrast study), Yes (by another study), No
Unknown, 
21 Age diagnosed as CKD under 10y.o, 10's, 20's, , , 70's, 80y.o. or over, Not yet, 
Unknown
22 Serum Albumin g/dL
23 Hematuria –, ±, +, 2 +, 3 + or over (Micro hematuria) , Macro 
hematuria
CIS of CKDID of CIS Item Unit, expression
CIS of diabetes 
mellitus
CIS of 
hypertension
CIS of 
Dyslipidemia
Figure 1 | Core item sets for diabetes mellitus, hypertension, dyslipidemia, and chronic kidney disease3.
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the triglyceride level is <400 mg/dL, LDL cholesterol by the
Friedewald formula (only in the fasting condition) or direct
assay, or non-HDL-cholesterol, should be used for the evalua-
tion; when the triglyceride level is in the range 400–600 mg/dL,
LDL cholesterol (by direct assay but not by the Friedewald for-
mula) or non-HDL-cholesterol should be used for the evalua-
tion; for triglyceride levels in the range 600–1,000 mg/dL, LDL
cholesterol by direct assay, but not by the Friedewald formula,
should be used for the evaluation; and when triglycerides
≥1,000 mg/dL, triglyceride should be improved before the eval-
uation of lipid-related indicators.
The JSLM subsequently mapped the SMISs to the JLAC10
(Table 1), and this map was approved by the CEC in 2018. Map-
ping the SMISs to JLAC10 is complicated because it depends on
factors, such as the assay methods and reagents used. Therefore,
when PHR providers install actual JLAC10 codes in the system,
they should be careful and ensure they use the correct codes.
DISCUSSION
‘Big data’ has evolved to incorporate clinical information, and it
is expected that a vast amount of diabetes-related data will be
generated. It is therefore important to develop and implement
standardized data item sets for diabetes-related databases. Link-
ing those databases to databases for other chronic diseases
should help generate useful, high-quality data. However,
attempts to standardize data item sets have often failed because
of an excessive number of items. In our approach, we deﬁned
the CIS for each disease and then developed SMISs based on
those CISs to minimize the number of items.
Our SMISs have been used in databases for three large dis-
ease registry studies (Table 2). For example, the Japan Diabetes
Comprehensive Database Project Based on an Advanced Elec-
tronic Medical Record System (J-DREAMS), administered by
the National Center for Global Health and Medicine and the
JDS, used all of our SMIS items for diabetes mellitus7,8. In
from Medical from health chekcup from home from Medical 
from health
check- up
from health
check- up
from health
check- upfrom home from Medical from home from Medical from home
1 Height cm
2 Weight kg
3 Systolic Blood Pressure mmHg
4 Diastolic Blood Pressure mmHg
5 LDL Cholesterol mg/dL
6 HDL Cholesterol mg/dL
7 Smoking Yes, No, Yes in the past
8 Serum Creatinine mg/dL
9 Urine Protein –, ±, +, 2 +, 3 + or over
10 Blood Glucose mg/dL
11 Age diagnosed as Diabetes Mellitus 
under 10y.o, 10's, 20's, , , 70's, 80y.o. or over, Not yet, 
Unknown
12 HbA1c %
13 ALT IU/L
14 Diabetic Retinopathy Yes, No, Unknown
15 Age diagnosed as Hypertension under 10y.o, 10's, 20's, , , 70's, 80y.o. or over, No, Unknown
16 Serum Potassium mEq/L
17 Abnormality on ECG Yes, No, Unknown
18 Triglyceride mg/dL
19 Age diagnosed as Dyslipidemia under 10y.o, 10's, 20's, , , 70's, 80y.o. or over, No, Unknown
20 Past History of Coronary Diseases Yes (by contrast study), Yes (by another study), No, Unknown
21 Age diagnosed as CKD under 10y.o, 10's, 20's, , , 70's, 80y.o. or over, No, Unknown
22 Serum Albumin g/dL
23 Hematuria –, ±, +, 2 +, 3 + or over (Micro hematuria) , Macro hematuria
24 Total Cholesterol mg/dL
25 Urine Albumin/Creatinine mg/gCre
26 AST IU/L
27 Waist cm
28 Urine Glucose –, ±, +, 2 + or over
29 γ GTP IU/L
30 Diabetic neuropathy Yes, No, Unknown
31 Regular visit at Dental Clinic (*1) Yes, No, Unknown
32 Uric Acid mg/dL
33 Systolic Blood Pressure at home mmHg
34 Diastolic Blood Pressure at home mmHg
35 Family History of Renal Failure(*2) Yes, No, Unknown
36 Urine Protein /Creatinine g/gCre
37 Urine Protein / Day g/day
38 Serum Total Protein g/dL
39 BUN mg/dL
40 Hemoglobin g/dL
41 Cystatin C mg/L
ID of 
SMIS Item Unit, expression
SMIS for Diabetes Mellitus SMIS for Hypertension SMIS for Dyslipidemia SMIS for CKD
CIS for Diabetes Mellitus CIS for Hypertension CIS for Dyslipidemia CIS for CKD
Figure 2 | The self-management item sets3.
Notes: (*1) Regular visits to a dental clinic (at least once per year). (*2) A family history of renal failure, including hemodialysis, renal transplantation,
or renal failure in a family member of ≤2 degrees of separation
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Table 1 | Mapping similarities between the self-management item set and the Japan Laboratory Analysis Code version 10 (JLAC10)
Number Item name Expression/unit JLAC10 code Supplement
1 Hight cm 9N001000000000001
2 Weight kg 9N006000000000001
3 Systolic blood pressure mmHg 9A751000000000001
4 Diastolic blood pressure mmHg 9A761000000000001
5 LDL-cholesterol mg/dL 3F077000002327101
3F077000002391901 Friedewald
6 HDL cholesterol mg/dL 3F070000002327101
7 Smoking Yes, No, Yes in the past 9N736000000000011
8 Serum creatinin mg/dL 3C015000002327101
9 Urine protein -, –,+, 2+, 3+or over 1A990000000190153 Urinary test strip method
10 Blood glucose mg/dL 3D010****01927201 NaF,Plasma
**** [1,288: before breakfast,
1,289: after breakfast, 1,290:
before lunch, 1,291:
after lunch, 1,292:
before supper, 1,293:
after supper, 1,299:
casual, 1,300: fasting]
11 Age diagnosed as diabetes mellitus Less than 10y.o, 10s, 20s,
70s, 80 y.o or over, Unknown
9N041000000000011
12 HbA1c (NGSP) % 3D046000001920402
13 ALT IU/L 3B045000002327201
14 Diabetic retinopathy Yes, No, Unknow 9N042000000000011
15 Age diagnosed as hypertension Less than 10y.o, 10s, 20s,
70s, 80 y.o or over, Unknown
9N043000000000011
16 Serum potacium mEq/L 3H015000002326101
17 Abnormality on ECG Yes, No, Unknow 9A110160700000011
18 Trigriceride mg/dL 3F0150****2327101
**** [1,288: before
breakfast, 1,289:
after breakfast, 1,290:
before lunch, 1,291:
after lunch, 1,292:
before supper, 1,293:
after supper, 1,299:
casual, 1,300: fasting]
19 Age diagnosed as dyslipidemia Less than 10y.o, 10s, 20s, 70s,
80 y.o or over, Unknown
9N044000000000011
20 Past history of coronary diseases Yes (by contrast study), Yes
(by another study), No, Unknown
9N721000000000011
21 Age diagnosed as CKD Less than 10y.o, 10s, 20s, 70s,
80 y.o or over, Unknown
9N045000000000011
22 Serum albumin g/dL 3A015000002327101
23 Hematuria -, –,+, 2+, 3+or over
(Micro hematuria), Macrohematuria
1A990000000190159 Urinary test strip method
24 Total cholesterol mg/dL 3F050000002327101
Non-HDL-cholesterol mg/dL 3F069000002391901
25 Urine albumin/Creatinin mg/gCr 3A015000000106128
26 AST IU/L 3B035000002327201
27 Waist cm 9N016160100000001
28 Urine glucose -, –,+, 2+or over 1A990****00190154 Urinary test strip method
1A020****00190111 Specific health check-up code
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addition, J-CDK-DB9, administered by the JSN, used some of
the CKD SMIS items, which can be automatically output from
the SS-MIX2 system10, and the Japan Medical Association Dia-
betes Database of Clinical Medicine (J-DOME), administered
by the Japan Medical Association to collect clinical information
about diabetes, used all of our SMIS items for all four chronic
diseases11.
We implemented all the SMIS items for the four chronic dis-
eases with detailed speciﬁcations for their inclusion in a PHR
application that is being developed as part of the MEDIS-DC
Table 1 (Continued)
Number Item name Expression/unit JLAC10 code Supplement
**** [,1288: before
breakfast, 1,289: after breakfast,
1,290: before lunch, 1,291:
after lunch, 1,292:
before supper, 1,293:
after supper, 1,299:
casual, 1,300: fasting]
29 c-GTP IU/L 3B090000002327101
30 Diabeteic neuropathy Yes, No, Unknown 9N046000000000011
31 Regular visit at dental clinic Yes, No, Unknown 9N531000000000011
32 Uric acid mg/dL 3C020000002327101
33 Systolic blood pressure at home mmHg 9A751000000099501
34 Diastolic blood pressure at home mmHg 9A761000000099501
35 Family history of renal failure Yes, No, Unknown 9N047000000000011
36 Urine protein/Creatinin g/gCr 1A015000000127128
37 Urine protein/Day g/day 1A015000000427126
38 Serum total protein g/dL 3A010000002327101
39 BUN mg/dL 3C025000002327201
40 Hemoglobin g/dL 2A990000001930953
2A030000001930901 Specific health check-up code
41 Cystatin C mg/L 3C016000002306201
Extra Items Weight at home kg 9N006000000099401
Extra Items Self-monitoring blood glucose mg/dL 3D010****01899101
**** [1,288:before
breakfast, 1,289: after breakfast,
1,290: before lunch, 1,291:
after lunch, 1,292:
before supper, 1,293:
after supper, 1,299:
casual, 1,300: fasting]
Copyright © 2018, The Collaborative Extended Committee by Six Japanese Academic Associations for Chronic Diseases, All Rights Reserved.
Table 2 | Outline timetable of implementation using the self-management item set (SMIS) and the recommended configuration for personal
health records (PHRs)
Startup Diabetes SMIS Hypertension SMIS Dyslipidemia SMIS CKD SMIS Specification for PHR
Case Registration cohort
J-DREAMS 2015~ ◎ – – – –
J-CKD-DB 2015~ – – – ○ –
J-DOME 2016~ ◎ ◎ ◎ ◎ –
PHR project
PHR (by MEDIS-DC) 2016~ ◎ ◎ ◎ ◎ ◎
PHR (DialBetics) 2018~? ○ (planned) – – ○ (planned) ○ (planned)
◎: full implementation, ○: partial implementation.
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project, funded by AMED. We are also conducting veriﬁcation
studies in the cities of Nishinomiya (Hyogo Prefecture), Taku
(Saga Prefecture), and Koriyama (Fukushima Prefecture).
Finally, another PHR project, ‘Expanding and strengthening
cooperation of a CKD database and establishment of a compre-
hensive database,’ initiated in 2017 and also funded by AMED,
is using our diabetes-related SMIS items in the ‘DialBetics’
PHR application12.
CONCLUSIONS
In conclusion, CCCIDM and the CEC established standardized
CISs and SMISs for the four chronic diseases. They also devel-
oped speciﬁcations for implementing these items in PHR appli-
cations, such as identifying values for risk stratiﬁcation,
generating alerts using information and communications tech-
nology systems, avoiding data input errors, and generating
reminders to input the SIMS data. In addition, a table was
developed to map the item sets to the JLAC10 codes.
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Table S1 | Recommended conﬁguration for personal health records based on the self-management item set for healthy people (the
basic conﬁguration).
Table S2 | Recommended conﬁguration for personal health records based on the self-management item set for patients with dia-
betes mellitus (the diabetic conﬁguration).
Table S3 | Recommended conﬁguration for personal health records based on the self-management item set for patients with hyper-
tension (the hypertension conﬁguration).
Table S4 | Recommended conﬁguration for personal health records based on the self-management item set for patients with dys-
lipidemia (the dyslipidemia conﬁguration).
Table S5 | Recommended conﬁguration for personal health records based on the self-management item set for patients with
chronic kidney disease (the CKD conﬁguration).
Table S6 | Recommended conﬁguration for personal health records based on the self-management item set for patients with coro-
nary heart disease (the coronary heart disease conﬁguration).
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